Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging

Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging Publisher Pubmed

Oveisi M ; Ebrahimi F ; Bitarafan Rajabi A ; Dastgir M ; Ghasemi Shayan RG ; Akbari T ; Ardestani MS ; Darbandiazar A ; Abaei S ; Foroumadi A ; Ramazani A ; Mortezazadeh T ; Khoobi M

Source: Biomaterials Advances Published:2026

Abstract

Chelator-free radiolabeling of nanoparticles (NPs) has attracted a great interest in design of targeted contrast agents for multimodal imaging. Herein, we present a new dual-modality contrast agent based on the efficient radiolabeling of Fe3O4 magnetic nanoparticles (MNPs) with 99mTc for targeted MRI-SPECT cancer imaging. Methionine (Met) was conjugated to maleic anhydride-alt-1-octadecene (PMAO) and employed as a coating agent, endowing Fe3O4 MNPs with appropriate colloidal stability, biocompatibility, binding affinity to 99mTc, and targeting ability. The morphology, size, surface charge, crystallinity and functionality of the targeted contrast agent (Fe3O4@PMAO-Met) were fully characterized. The MTT assay confirmed high biocompatibility of Fe3O4@PMAO-Met MNPs (∼35 nm) in MCF-10A normal mammary epithelial cells, and enhanced uptake in MCF-7 breast cancer cells, supporting their targeting capability. The 99mTc-labeled MNPs with reproducible high yield (>98 %) at room temperature remained permanent in vitro for 24 h in saline and for 6 h in human serum. Fe3O4@PMAO-Met MNPs was also evaluated in vivo in mice models, exhibiting acceptable tumor visualization as well as noticeable hepatobiliary uptake with low accumulation in non-target organs. In vivo MR imaging of Balb/c mice revealed a negative T2 enhanced contrast on tumor cells. All assessments demonstrated high potential of Fe3O4@PMAO-Met-99mTc for further analyses as a promising targeted contrast agent in MRI-SPECT cancer imaging. © 2025 Elsevier B.V., All rights reserved.

Style	Citing Format
MLA	Oveisi M, et al.. "Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging." Biomaterials Advances, vol. 180, no. , 2026, pp. -.
APA	Oveisi M, Ebrahimi F, Bitarafan Rajabi A, Dastgir M, Ghasemi Shayan RG, Akbari T, Ardestani MS, Darbandiazar A, Abaei S, Foroumadi A, Ramazani A, Mortezazadeh T, Khoobi M (2026). Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging. Biomaterials Advances, 180(), -.
Chicago	Oveisi M, Ebrahimi F, Bitarafan Rajabi A, Dastgir M, Ghasemi Shayan RG, Akbari T, Ardestani MS, et al.. "Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging." Biomaterials Advances 180, no. (2026): -.
Harvard	Oveisi M et al. (2026) 'Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging', Biomaterials Advances, 180(), pp. -.
Vancouver	Oveisi M, Ebrahimi F, Bitarafan Rajabi A, Dastgir M, Ghasemi Shayan RG, Akbari T, et al.. Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging. Biomaterials Advances. 2026;180():-.
BibTex	@article{ author = {Oveisi M and Ebrahimi F and Bitarafan Rajabi A and Dastgir M and Ghasemi Shayan RG and Akbari T and Ardestani MS and Darbandiazar A and Abaei S and Foroumadi A and Ramazani A and Mortezazadeh T and Khoobi M}, title = {Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging}, journal = {Biomaterials Advances}, volume = {180}, number = {}, pages = {-}, year = {2026} }
RIS	TY - JOUR AU - Oveisi M AU - Ebrahimi F AU - Bitarafan Rajabi A AU - Dastgir M AU - Ghasemi Shayan RG AU - Akbari T AU - Ardestani MS AU - Darbandiazar A AU - Abaei S AU - Foroumadi A AU - Ramazani A AU - Mortezazadeh T AU - Khoobi M TI - Ph-Sensitive Methionine-Decorated Magnetite for Targeted Mri/Spect Cancer Imaging JO - Biomaterials Advances VL - 180 IS - SP - EP - PY - 2026 ER -

Science Communicator Platform

Authors

Abstract